The serotonin-BDNF duo: Developmental implications for the vulnerability to psychopathology

Neuroscience and Biobehavioral Reviews

Volumn 43, Issue , 2014, Pages 35-47

  Homberg, Judith Regina ^a   Molteni, Raffaella ^b   Calabrese, Francesca ^b   Riva, Marco A ^b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

5 HTT; BDNF; Depression; DNA methylation; Neurodevelopment; Serotonin; Transcription factors

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; MESSENGER RNA; NEUROTROPHIN; SEROTONIN; SEROTONIN 4 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRANSCRIPTION FACTOR; TRANYLCYPROMINE;

BEHAVIOR; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN REGION; DNA METHYLATION; DNA MODIFICATION; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; GENETIC MANIPULATION; HIPPOCAMPUS; HUMAN; INTRACELLULAR SIGNALING; MENTAL DISEASE; NONHUMAN; PERINATAL PERIOD; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; SEROTONINERGIC SYSTEM; ANIMAL; BRAIN; METABOLISM; NERVE CELL PLASTICITY; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; NEURONAL PLASTICITY; PSYCHOPATHOLOGY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84899140406     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.03.012     Document Type: Review

References (153)

1. Aguilera M., Arias B., Wichers M., Barrantes-Vidal N., Moya J., Villa H., van Os J., Ibanez M.I., Ruiperez M.A., Ortet G., Fananas L. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol. Med. 2009, 39(9):1425-1432.
2. Aid T., Kazantseva A., Piirsoo M., Palm K., Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 2007, 85(3):525-535.
3. An J.J., Gharami K., Liao G.Y., Woo N.H., Lau A.G., Vanevski F., Torre E.R., Jones K.R., Feng Y., Lu B., Xu B. Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 2008, 134(1):175-187.
4. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306(5697):879-881.
5. Baj G., Leone E., Chao M.V., Tongiorgi E. Spatial segregation of BDNF transcripts enables BDNF to differentially shape distinct dendritic compartments. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(40):16813-16818.
6. Bath K.G., Jing D.Q., Dincheva I., Neeb C.C., Pattwell S.S., Chao M.V., Lee F.S., Ninan I. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012, 37(5):1297-1304.
7. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25(1):1-27.
8. Benmansour S., Deltheil T., Piotrowski J., Nicolas L., Reperant C., Gardier A.M., Frazer A., David D.J. Influence of brain-derived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents. Eur. J. Pharmacol. 2008, 587(1-3):90-98.
9. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7(2):137-151.
10. Bhang S., Ahn J.H., Choi S.W. Brain-derived neurotrophic factor and serotonin transporter gene-linked promoter region genes alter serum levels of brain-derived neurotrophic factor in humans. J. Affect. Disord. 2011, 128(3):299-304.
11. Boulle F., van den Hove D.L., Jakob S.B., Rutten B.P., Hamon M., van Os J., Lesch K.P., Lanfumey L., Steinbusch H.W., Kenis G. Epigenetic regulation of the BDNF gene: implications for psychiatric disorders. Mol. Psychiatry 2012, 17(6):584-596.
12. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Mol. Psychiatry 2003, 8(8):721-737. 715.
13. Branchi I., Santarelli S., Capoccia S., Poggini S., D'Andrea I., Cirulli F., Alleva E. Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. PLOS ONE 2013, 8(4):e62226.
14. Burke T.F., Advani T., Adachi M., Monteggia L.M., Hensler J.G. Sensitivity of hippocampal 5-HT1A receptors to mild stress in BDNF-deficient mice. Int. J. Neuropsychopharmacol. 2013, 16(3):631-645.
15. Calabrese F., Guidotti G., Middelman A., Racagni G., Homberg J., Riva M.A. Lack of serotonin transporter alters BDNF expression in the rat brain during early postnatal development. Mol. Neurobiol. 2013, 48(1):244-256.
16. Calabrese F., Molteni R., Cattaneo A., Macchi F., Racagni G., Gennarelli M., Ellenbroek B.A., Riva M.A. Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Mol. Pharmacol. 2010, 77(5):846-853.
17. Calabrese F., Molteni R., Gabriel C., Mocaer E., Racagni G., Riva M.A. Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl.) 2011, 215(2):267-275.
18. Calabrese F., Molteni R., Maj P.F., Cattaneo A., Gennarelli M., Racagni G., Riva M.A. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007, 32(11):2351-2359.
19. Calabrese F., Molteni R., Racagni G., Riva M.A. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 2009, 34(Suppl. 1):S208-S216.
20. Calabrese F., Molteni R., Riva M.A. Antistress properties of antidepressant drugs and their clinical implications. Pharmacol. Ther. 2011, 132(1):39-56.
21. Carola V., Frazzetto G., Pascucci T., Audero E., Puglisi-Allegra S., Cabib S., Lesch K.P., Gross C. Identifying molecular substrates in a mouse model of the serotonin transporter×environment risk factor for anxiety and depression. Biol. Psychiatry 2008, 63(9):840-846.
22. Casarotto P.C., de Bortoli V.C., Zangrossi H. Intrahippocampal injection of brain-derived neurotrophic factor increases anxiety-related, but not panic-related defensive responses: involvement of serotonin. Behav. Pharmacol. 2012, 23(1):80-88.
23. Caspi A., Hariri A.R., Holmes A., Uher R., Moffitt T.E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 2010, 167(5):509-527.
24. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301(5631):386-389.
25. Cassel S., Carouge D., Gensburger C., Anglard P., Burgun C., Dietrich J.B., Aunis D., Zwiller J. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 2006, 70(2):487-492.
26. Cattaneo A., Sesta A., Calabrese F., Nielsen G., Riva M.A., Gennarelli M. The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 2010, 35(7):1423-1428.
27. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 2001, 50(4):260-265.
28. Chen W.G., Chang Q., Lin Y., Meissner A., West A.E., Griffith E.C., Jaenisch R., Greenberg M.E. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003, 302(5646):885-889.
29. 2+-responsive transcription in neurons. J. Neurosci. 2003, 23(7):2572-2581.
30. Chen Z.Y., Jing D., Bath K.G., Ieraci A., Khan T., Siao C.J., Herrera D.G., Toth M., Yang C., McEwen B.S., Hempstead B.L., Lee F.S. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314(5796):140-143.
31. Cohen S., Greenberg M.E. Communication between the synapse and the nucleus in neuronal development, plasticity, and disease. Annu. Rev. Cell Dev. Biol. 2008, 24:183-209.
32. Cohen-Cory S., Kidane A.H., Shirkey N.J., Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev. Neurobiol. 2010, 70(5):271-288.
33. Comasco E., Aslund C., Oreland L., Nilsson K.W. Three-way interaction effect of 5-HTTLPR, BDNF Val66Met, and childhood adversity on depression: a replication study. Eur. Neuropsychopharmacol. 2013.
34. Cools R., Roberts A.C., Robbins T.W. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn. Sci. 2008, 12(1):31-40.
35. Coppell A.L., Pei Q., Zetterstrom T.S. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003, 44(7):903-910.
36. Daws L.C., Munn J.L., Valdez M.F., Frosto-Burke T., Hensler J.G. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J. Neurochem. 2007, 101(3):641-651.
37. de Foubert G., O'Neill M.J., Zetterstrom T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience 2007, 147(3):778-785.
38. Deakin J.F., Graeff F.G. 5-HT and mechanisms of defence. J. Psychopharmacol. 1991, 5(4):305-315.
39. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Reperant C., Guilloux J.P., Coudore F., Hen R., Gardier A.M. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55(6):1006-1014.
40. Deltheil T., Guiard B.P., Guilloux J.P., Nicolas L., Delomenie C., Reperant C., Le Maitre E., Leroux-Nicollet I., Benmansour S., Coudore F., David D.J., Gardier A.M. Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: studies in adult mice hippocampus. Pharmacol. Biochem. Behav. 2008, 90(2):174-183.
41. Deltheil T., Tanaka K., Reperant C., Hen R., David D.J., Gardier A.M. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. Int. J. Neuropsychopharmacol. 2009, 12(7):905-915.
42. Deneris E.S. Molecular genetics of mouse serotonin neurons across the lifespan. Neuroscience 2011, 197:17-27.
43. Djalali S., Holtje M., Grosse G., Rothe T., Stroh T., Grosse J., Deng D.R., Hellweg R., Grantyn R., Hortnagl H., Ahnert-Hilger G. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J. Neurochem. 2005, 92(3):616-627.
44. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59(12):1116-1127.
45. Duric V., Duman R.S. Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell. Mol. Life Sci. 2013, 70(1):39-53.
46. Eaton M.J., Staley J.K., Globus M.Y., Whittemore S.R. Developmental regulation of early serotonergic neuronal differentiation: the role of brain-derived neurotrophic factor and membrane depolarization. Dev. Biol. 1995, 170(1):169-182.
47. Ebert D.H., Gabel H.W., Robinson N.D., Kastan N.R., Hu L.S., Cohen S., Navarro A.J., Lyst M.J., Ekiert R., Bird A.P., Greenberg M.E. Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature 2013, 499(7458):341-345.
48. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
49. Erspamer V., Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952, 169(4306):800-801.
50. Fanselow M.S., Dong H.W. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65(1):7-19.
51. Fumagalli F., Calabrese F., Luoni A., Bolis F., Racagni G., Riva M.A. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int. J. Neuropsychopharmacol. 2012, 15(2):235-246.
52. Fumagalli F., Molteni R., Racagni G., Riva M.A. Stress during development: impact on neuroplasticity and relevance to psychopathology. Prog. Neurobiol. 2007, 81(4):197-217.
53. Galter D., Unsicker K. Sequential activation of the 5-HT1(A) serotonin receptor and TrkB induces the serotonergic neuronal phenotype. Mol. Cell. Neurosci. 2000, 15(5):446-455.
54. Gardier A.M. Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor. Behav. Pharmacol. 2009, 20(1):18-32.
55. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 2003, 4(12):1002-1012.
56. Gatt J.M., Nemeroff C.B., Dobson-Stone C., Paul R.H., Bryant R.A., Schofield P.R., Gordon E., Kemp A.H., Williams L.M. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol. Psychiatry 2009, 14(7):681-695.
57. Grabe H.J., Schwahn C., Mahler J., Appel K., Schulz A., Spitzer C., Fenske K., Barnow S., Freyberger H.J., Teumer A., Petersmann A., Biffar R., Rosskopf D., John U., Volzke H. Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36(2):264-270.
58. Greenberg M.E., Xu B., Lu B., Hempstead B.L. New insights in the biology of BDNF synthesis and release: implications in CNS function. J. Neurosci. 2009, 29(41):12764-12767.
59. Guiard B.P., David D.J., Deltheil T., Chenu F., Le Maitre E., Renoir T., Leroux-Nicollet I., Sokoloff P., Lanfumey L., Hamon M., Andrews A.M., Hen R., Gardier A.M. Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. Int. J. Neuropsychopharmacol. 2008, 11(1):79-92.
60. Guidotti G., Calabrese F., Auletta F., Olivier J., Racagni G., Homberg J., Riva M.A. Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment. Neuropsychopharmacology 2012, 37(3):746-758.
61. Hassel S., McKinnon M.C., Cusi A.M., Macqueen G.M. An overview of psychological and neurobiological mechanisms by which early negative experiences increase risk of mood disorders. J. Can. Acad. Child Adolesc. Psychiatry 2011, 20(4):277-288.
62. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 1996, 66(6):2621-2624.
63. Heim C., Binder E.B. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp. Neurol. 2012, 233(1):102-111.
64. Hensler J.G., Advani T., Monteggia L.M. Regulation of serotonin-1A receptor function in inducible brain-derived neurotrophic factor knockout mice after administration of corticosterone. Biol. Psychiatry 2007, 62(5):521-529.
65. Hill R.A., Murray S.S., Halley P.G., Binder M.D., Martin S.J., van den Buuse M. Brain-derived neurotrophic factor expression is increased in the hippocampus of 5-HT(2C) receptor knockout mice. Hippocampus 2011, 21(4):434-445.
66. Homberg J.R. Serotonin and decision making processes. Neurosci. Biobehav. Rev. 2012, 36(1):218-236.
67. Homberg J.R., De Boer S.F., Raaso H.S., Olivier J.D., Verheul M., Ronken E., Cools A.R., Ellenbroek B.A., Schoffelmeer A.N., Vanderschuren L.J., De Vries T.J., Cuppen E. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl.) 2008, 200(3):367-380.
68. Homberg J.R., Lesch K.P. Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 2011, 69(6):513-519.
69. Homberg J.R., Schubert D., Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol. Sci. 2010, 31(2):60-65.
70. Hong E.J., McCord A.E., Greenberg M.E. A biological function for the neuronal activity-dependent component of BDNF transcription in the development of cortical inhibition. Neuron 2008, 60(4):610-624.
71. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
72. Hulsken S., Martin A., Mohajeri M.H., Homberg J.R. Food-derived serotonergic modulators: effects on mood and cognition. Nutr. Res. Rev. 2013, 26(2):223-234.
73. Iniguez S.D., Warren B.L., Bolanos-Guzman C.A. Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats. Biol. Psychiatry 2010, 67(11):1057-1066.
74. Jiang X., Tian F., Du Y., Copeland N.G., Jenkins N.A., Tessarollo L., Wu X., Pan H., Hu X.Z., Xu K., Kenney H., Egan S.E., Turley H., Harris A.L., Marini A.M., Lipsky R.H. BHLHB2 controls BDNF promoter 4 activity and neuronal excitability. J. Neurosci. 2008, 28(5):1118-1130.
75. Kalueff A.V., Olivier J.D., Nonkes L.J., Homberg J.R. Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neurosci. Biobehav. Rev. 2010, 34(3):373-386.
76. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 2011, 68(5):444-454.
77. Khundakar A.A., Zetterstrom T.S. Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res. 2006, 1106(1):12-20.
78. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006, 31(2):89-97.
79. Kozisek M.E., Middlemas D., Bylund D.B. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol. Ther. 2008, 117(1):30-51.
80. Kriegebaum C., Gutknecht L., Schmitt A., Lesch K.P., Reif A. Serotonin now: Part 1. Neurobiology and developmental genetics. Fortschr. Neurol. Psychiatr. 2010, 78(6):319-331.
81. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7(Suppl. 1):S71-S80.
82. Kuipers S.D., Bramham C.R. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr. Opin. Drug Discov. Devel. 2006, 9(5):580-586.
83. Lau A.G., Irier H.A., Gu J., Tian D., Ku L., Liu G., Xia M., Fritsch B., Zheng J.Q., Dingledine R., Xu B., Lu B., Feng Y. Distinct 3'UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). Proc. Natl. Acad. Sci. U. S. A. 2010, 107(36):15945-15950.
84. Lesch K.P. Molecular foundation of anxiety disorders. J. Neural Transm. 2001, 108(6):717-746.
85. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274(5292):1527-1531.
86. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6(4):312-324.
87. Lin Y., Bloodgood B.L., Hauser J.L., Lapan A.D., Koon A.C., Kim T.K., Hu L.S., Malik A.N., Greenberg M.E. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature 2008, 455(7217):1198-1204.
88. Lu B., Chang J.H. Regulation of neurogenesis by neurotrophins: implications in hippocampus-dependent memory. Neuron Glia Biol. 2004, 1(4):377-384.
89. Luoni A., Hulsken S., Cazzaniga G., Racagni G., Homberg J.R., Riva M.A. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int. J. Neuropsychopharmacol. 2013, 16(6):1319-1330.
90. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., Bora S.H., Wihler C., Koliatsos V.E., Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(26):15239-15244.
91. Mahar I., Bambico F.R., Mechawar N., Nobrega J.N. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci. Biobehav. Rev. 2013.
92. Mamounas L.A., Altar C.A., Blue M.E., Kaplan D.R., Tessarollo L., Lyons W.E. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J. Neurosci. 2000, 20(2):771-782.
93. Maragnoli M.E., Fumagalli F., Gennarelli M., Racagni G., Riva M.A. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol. Psychiatry 2004, 55(11):1095-1102.
94. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008, 33(1):73-83.
95. Masi G., Brovedani P. The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs 2011, 25(11):913-931.
96. Maya Vetencourt J.F., Sale A., Viegi A., Baroncelli L., De Pasquale R., O'Leary O.F., Castren E., Maffei L. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008, 320(5874):385-388.
97. Maya Vetencourt J.F., Tiraboschi E., Spolidoro M., Castren E., Maffei L. Serotonin triggers a transient epigenetic mechanism that reinstates adult visual cortex plasticity in rats. Eur. J. Neurosci. 2011, 33(1):49-57.
98. McDowell K.A., Hutchinson A.N., Wong-Goodrich S.J., Presby M.M., Su D., Rodriguiz R.M., Law K.C., Williams C.L., Wetsel W.C., West A.E. Reduced cortical BDNF expression and aberrant memory in Carf knock-out mice. J. Neurosci. 2010, 30(22):7453-7465.
99. McGowan P.O., Szyf M. The epigenetics of social adversity in early life: implications for mental health outcomes. Neurobiol. Dis. 2010, 39(1):66-72.
100. Miceli S., Negwer M., van Eijs F., Kalkhoven C., van Lierop I., Homberg J., Schubert D. High serotonin levels during brain development alter the structural input-output connectivity of neural networks in the rat somatosensory layer IV. Front. Cell. Neurosci. 2013, 7:88.
101. Migliarini S., Pacini G., Pelosi B., Lunardi G., Pasqualetti M. Lack of brain serotonin affects postnatal development and serotonergic neuronal circuitry formation. Mol. Psychiatry 2013, 18(10):1106-1118.
102. Minichiello L. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 2009, 10(12):850-860.
103. Molteni R., Calabrese F., Cattaneo A., Mancini M., Gennarelli M., Racagni G., Riva M.A. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology 2009, 34(6):1523-1532.
104. Molteni R., Cattaneo A., Calabrese F., Macchi F., Olivier J.D., Racagni G., Ellenbroek B.A., Gennarelli M., Riva M.A. Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. Neurobiol. Dis. 2010, 37(3):747-755.
105. Morita K., Gotohda T., Arimochi H., Lee M.S., Her S. Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. J. Neurosci. Res. 2009, 87(11):2608-2614.
106. Munafo M.R., Brown S.M., Hariri A.R. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 2008, 63(9):852-857.
107. Narboux-Neme N., Pavone L.M., Avallone L., Zhuang X., Gaspar P. Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). Neuropharmacology 2008, 55(6):994-1005.
108. Nugent N.R., Tyrka A.R., Carpenter L.L., Price L.H. Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. Psychopharmacology (Berl.) 2011, 214(1):175-196.
109. Olivier J.D., Van Der Hart M.G., Van Swelm R.P., Dederen P.J., Homberg J.R., Cremers T., Deen P.M., Cuppen E., Cools A.R., Ellenbroek B.A. A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 2008, 152(3):573-584.
110. Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013, 14(1):7-23.
111. Pascual-Brazo J., Castro E., Diaz A., Valdizan E.M., Pilar-Cuellar F., Vidal R., Treceno B., Pazos A. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333. Int. J. Neuropsychopharmacol. 2012, 15(5):631-643.
112. Pergamin-Hight L., Bakermans-Kranenburg M.J., van Ijzendoorn M.H., Bar-Haim Y. Variations in the promoter region of the serotonin transporter gene and biased attention for emotional information: a meta-analysis. Biol. Psychiatry 2012, 71(4):373-379.
113. Pilar-Cuellar F., Vidal R., Pazos A. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects. Br. J. Pharmacol. 2012, 165(4b):1046-1057.
114. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2(1):24-32.
115. Pruunsild P., Kazantseva A., Aid T., Palm K., Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007, 90(3):397-406.
116. Ren-Patterson R.F., Cochran L.W., Holmes A., Sherrill S., Huang S.J., Tolliver T., Lesch K.P., Lu B., Murphy D.L. Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. J. Neurosci. Res. 2005, 79(6):756-771.
117. Rios M., Lambe E.K., Liu R., Teillon S., Liu J., Akbarian S., Roffler-Tarlov S., Jaenisch R., Aghajanian G.K. Severe deficits in 5-HT2A-mediated neurotransmission in BDNF conditional mutant mice. J. Neurobiol. 2006, 66(4):408-420.
118. Risch N., Herrell R., Lehner T., Liang K.Y., Eaves L., Hoh J., Griem A., Kovacs M., Ott J., Merikangas K.R. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009, 301(23):2462-2471.
119. Roceri M., Cirulli F., Pessina C., Peretto P., Racagni G., Riva M.A. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol. Psychiatry 2004, 55(7):708-714.
120. Rossi C., Angelucci A., Costantin L., Braschi C., Mazzantini M., Babbini F., Fabbri M.E., Tessarollo L., Maffei L., Berardi N., Caleo M. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur. J. Neurosci. 2006, 24(7):1850-1856.
121. Roth T.L., Lubin F.D., Funk A.J., Sweatt J.D. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol. Psychiatry 2009, 65(9):760-769.
122. Rumajogee P., Verge D., Hanoun N., Brisorgueil M.J., Hen R., Lesch K.P., Hamon M., Miquel M.C. Adaption of the serotoninergic neuronal phenotype in the absence of 5-HT autoreceptors or the 5-HT transporter: involvement of BDNF and cAMP. Eur. J. Neurosci. 2004, 19(4):937-944.
123. Sairanen M., Lucas G., Ernfors P., Castren M., Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 2005, 25(5):1089-1094.
124. Sakata K., Woo N.H., Martinowich K., Greene J.S., Schloesser R.J., Shen L., Lu B. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(14):5942-5947.
125. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., Berman R.M., Charney D.S., Krystal J.H. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 1999, 56(11):1043-1047.
126. Savitz J., Solms M., Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 2006, 5(4):311-328.
127. Schinka J.A., Busch R.M., Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol. Psychiatry 2004, 9(2):197-202.
128. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. 2007, 18(5-6):391-418.
129. Schmidt H.D., Shelton R.C., Duman R.S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011, 36(12):2375-2394.
130. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 2007, 62(1):55-64.
131. Schweigreiter R. The dual nature of neurotrophins. Bioessays 2006, 28(6):583-594.
132. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64(6):527-532.
133. Shioe K., Ichimiya T., Suhara T., Takano A., Sudo Y., Yasuno F., Hirano M., Shinohara M., Kagami M., Okubo Y., Nankai M., Kanba S. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 2003, 48(4):184-188.
134. Sibille E., Su J., Leman S., Le Guisquet A.M., Ibarguen-Vargas Y., Joeyen-Waldorf J., Glorioso C., Tseng G.C., Pezzone M., Hen R., Belzung C. Lack of serotonin1B receptor expression leads to age-related motor dysfunction, early onset of brain molecular aging and reduced longevity. Mol. Psychiatry 2007, 12(11):1042-1056. 1975.
135. Siuciak J.A., Boylan C., Fritsche M., Altar C.A., Lindsay R.M. BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. Brain Res. 1996, 710(1-2):11-20.
136. Sun H., Kennedy P.J., Nestler E.J. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013, 38(1):124-137.
137. Szapacs M.E., Mathews T.A., Tessarollo L., Ernest Lyons W., Mamounas L.A., Andrews A.M. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J. Neurosci. Methods 2004, 140(1-2):81-92.
138. Tanti A., Belzung C. Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific?. Neuroscience 2013, 252:234-252.
139. Trajkovska V., Santini M.A., Marcussen A.B., Thomsen M.S., Hansen H.H., Mikkelsen J.D., Arneberg L., Kokaia M., Knudsen G.M., Aznar S. BDNF downregulates 5-HT(2A) receptor protein levels in hippocampal cultures. Neurochem. Int. 2009, 55(7):697-702.
140. Tripp A., Oh H., Guilloux J.P., Martinowich K., Lewis D.A., Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am. J. Psychiatry 2012, 169(11):1194-1202.
141. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9(4):519-525.
142. Twarog B.M., Page I.H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol. 1953, 175(1):157-161.
143. Vaidya V.A., Marek G.J., Aghajanian G.K., Duman R.S. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 1997, 17(8):2785-2795.
144. van Dyck C.H., Malison R.T., Staley J.K., Jacobsen L.K., Seibyl J.P., Laruelle M., Baldwin R.M., Innis R.B., Gelernter J. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am. J. Psychiatry 2004, 161(3):525-531.
145. Waterhouse E.G., An J.J., Orefice L.L., Baydyuk M., Liao G.Y., Zheng K., Lu B., Xu B. BDNF promotes differentiation and maturation of adult-born neurons through GABAergic transmission. J. Neurosci. 2012, 32(41):14318-14330.
146. Wu Y.C., Hill R.A., Klug M., van den Buuse M. Sex-specific and region-specific changes in BDNF-TrkB signalling in the hippocampus of 5-HT1A receptor and BDNF single and double mutant mice. Brain Res. 2012, 1452:10-17.
147. Xia L., Delomenie C., David I., Rainer Q., Marouard M., Delacroix H., David D.J., Gardier A.M., Guilloux J.P. Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT(1)A and 5-HT(1)B receptors disruption in mice. Neurosci. Lett. 2012, 521(1):20-25.
148. Yoshii A., Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev. Neurobiol. 2010, 70(5):304-322.
149. Yu H., Wang D.D., Wang Y., Liu T., Lee F.S., Chen Z.Y. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J. Neurosci. 2012, 32(12):4092-4101.
150. Zetterstrom T.S., Coppell A.A., Khundakar A.A. The role of 5-hydroxytryptamine receptor subtypes in the regulation of brain-derived neurotrophic factor gene expression. J. Pharm. Pharmacol. 2014, 66(1):53-61.
151. Zetterstrom T.S., Pei Q., Madhav T.R., Coppell A.L., Lewis L., Grahame-Smith D.G. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology 1999, 38(7):1063-1073.
152. Zhou J., Cao X., Mar A.C., Ding Y.Q., Wang X., Li Q., Li L. Activation of postsynaptic 5-HT receptors improve stress adaptation. Psychopharmacology (Berl.) 2013.
153. Zhou Z., Hong E.J., Cohen S., Zhao W.N., Ho H.Y., Schmidt L., Chen W.G., Lin Y., Savner E., Griffith E.C., Hu L., Steen J.A., Weitz C.J., Greenberg M.E. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52(2):255-269.